Novartis Licenses MedImmune's Reverse Genetics IP to Develop Flu Vaccine Strains

Aug 24, 2007

NEW YORK (GenomeWeb News) — MedImmune yesterday said it has licensed its reverse genetics intellectual property to Novartis to help the drug maker develop new influenza vaccine strains.

Terms of the deal call for MedImmune to receive an upfront payment from Novartis, as well as the potential to receive royalties on certain vaccine stockpiles or sales of other influenza products developed using the reverse genetics technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Last of the Northern White Rhinoceroses, Sequenced

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

DNA Phenotyping Allowed in Bavaria

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Thanks for the Stress, Dad

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

This Week in Science

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Main menu